SOPHARMA AD (97/2022) Notification from “Telso” AD under Art. 19 of Regulation (EU) No 596/2014 of 13 December 2022.

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering. Notification from “Telso” AD under Art. 19 of Regulation (EU) No 596/2014 of 13 December 2022. Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1 kom espi zdz Informacja dystrybuowana przez: pap-mediaroom.pl

Czytaj dalej

SOPHARMA AD (88/2022) Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering. “Sopharma” AD (the Company) announces that today, according to a decision of the Board of Directors dated November 28, 2022, the company concluded the following transaction falling within the scope of Art. 114, para. 2 of the LPOS: 1. “Sopharma” AD as a Lessee, concluded Annex ą 1 to …

Czytaj dalej

SOPHARMA AD (86/2022) Tender offer to the shareholders of “Sopharma” AD by “Donev Investments Holding” AD

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering. “Sopharma” AD (the Company) announces that on November 28, 2022, “Sopharma” AD received a tender offer registered with the Commission for Financial Supervision from “DONEV INVESTMENTS HOLDING” AD – a shareholder, directly owning 37,600,000 ordinary, dematerialized shares with voting rights, representing 27.89% of the capital and votes in the …

Czytaj dalej

SOPHARMA AD (83/2022) Merger of the subsidiary “Biopharm-engineering” AD into “Sopharma” AD

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering. “Sopharma” AD (the Company) notifies that the Board of Directors of “Sopharma” AD adopted a decision to initiate a procedure for the merger of the subsidiary “Biopharm-Engineering” AD, UIC: 119055339 in “Sopharma” AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 …

Czytaj dalej

Ostatnie komentarze

Brak komentarzy do wyświetlenia.